Personalised nanomedicine for cancer therapy

Chemists are building drug-carrying particles 100 times smaller than a cancer cell, designed to dissolve into harmless nutrients once they finish their work. The problem is that anticancer drugs cannot tell the difference between cancerous and healthy cells, because cancer cells are normal cells that have gone wrong. This means patients often suffer severe side effects from treatments that are nearly as damaging as the disease itself. Current targeting methods are too blunt to solve this. These nanocarriers—roughly the size of a virus—carry a chemical signature that lets them find cancer cells almost exclusively, deliver a large drug payload directly inside the cell, and then break down into substances the body already uses as nutrients. The key innovation is that the carriers will be built using a patient’s own tissue, creating a fully personalised targeting profile and drug dosage for each individual. If this works, cancer treatment could shift from a one-size-fits-all approach to a tailored therapy that spares healthy tissue while maximising the drug’s effect inside the tumour. That would mean fewer side effects and better outcomes for patients.